Analyst Consensus ?
ConsensusHold34 ratings
Bullish1338.2%
Neutral1647.1%
Bearish514.7%
FN2 Earnings Intelligence
ResMed Inc. analyst ratings
ResMed Inc. (RMD) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$218.27Current
$175Low
$250.69Average
$345High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 13, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Keybanc | Overweight | Overweight | Maintain | Aug 31, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jun 17, 2026 |
| Stifel | Hold | Hold | Maintain | Jan 30, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 24, 2025 |
| Needham | Hold | Hold | Maintain | Jan 31, 2025 |
| B of A Securities | Buy | Buy | Maintain | Sep 26, 2024 |
| Wolfe Research | Underperform | Peer Perform | Downgrade | Sep 18, 2024 |
| Oppenheimer | Perform | Outperform | Downgrade | Jun 25, 2024 |
| CLSA | Buy | Outperform | Maintain | Jan 13, 2022 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 6, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jul 29, 2019 |
| Deutsche Bank | Buy | Hold | Upgrade | Mar 20, 2019 |
| BMO Capital | Outperform | Market Perform | Upgrade | Dec 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Oct 27, 2017 |
| Credit Suisse | Neutral | Outperform | Downgrade | Aug 2, 2017 |
| Bank of America | Neutral | Buy | Downgrade | Aug 2, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 27, 2016 |
| BBY | Underperform | Underperform | Maintain | Feb 2, 2015 |
| Northland Securities | Underperform | Market Perform | Downgrade | May 27, 2014 |
| Northland Capital Markets | Underperform | Market Perform | Downgrade | May 27, 2014 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 24, 2014 |
| Shaw Stockbroking | Buy | Buy | Maintain | Sep 20, 2013 |
| S&P Capital IQ | Buy | Buy | Maintain | Feb 26, 2013 |
| CBA | Buy | Hold | Upgrade | Aug 7, 2012 |
| Feltl & Co. | Hold | Hold | Maintain | Aug 6, 2012 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $218.27. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| KeyBanc | Analyst unavailable | $267 | $240.33 | +22.3% | Aug 31, 2026 |
| Redburn Partners | Analyst unavailable | $230 | $219.98 | +5.4% | Aug 19, 2026 |
| Robert W. Baird | Analyst unavailable | $213 | $212.38 | -2.4% | Aug 7, 2026 |
| KeyBanc | Analyst unavailable | $255 | $223.24 | +16.8% | Aug 7, 2026 |
| UBS | David Low | $300 | $195.97 | +37.4% | Jul 21, 2026 |
| RBC Capital | Analyst unavailable | $234 | $198.57 | +7.2% | Jul 16, 2026 |
| Mizuho Securities | Analyst unavailable | $220 | $193.01 | +0.8% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $225 | $204.5 | +3.1% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $276 | $219.75 | +26.4% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $225 | $219.75 | +3.1% | Jul 8, 2026 |
| KeyBanc | Analyst unavailable | $266 | $188.63 | +21.9% | Jun 22, 2026 |
| Morgan Stanley | David Bailey | $230 | $193.94 | +5.4% | Jun 17, 2026 |
| Robert W. Baird | Analyst unavailable | $225 | $203.87 | +3.1% | May 1, 2026 |
| KeyBanc | Analyst unavailable | $290 | $219.85 | +32.9% | Apr 27, 2026 |
| Evercore ISI | Anthony Petrone | $255 | $228.33 | +16.8% | Apr 13, 2026 |
| RBC Capital | Craig Wong-Pan | $314 | $254.08 | +43.9% | Jan 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $265 | $257.61 | +21.4% | Jan 30, 2026 |
| KeyBanc | Brett Fishbin | $302 | $257.61 | +38.4% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $281 | $257.61 | +28.7% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $275 | $257.61 | +26.0% | Jan 30, 2026 |
| Stifel Nicolaus | Jonathan Block | $260 | $245.94 | +19.1% | Dec 18, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $253.07 | +26.0% | Dec 16, 2025 |
| UBS | Marcus Curley | $345 | $251.38 | +58.1% | Dec 12, 2025 |
| Robert W. Baird | Analyst unavailable | $300 | $246.88 | +37.4% | Nov 3, 2025 |
| KeyBanc | Brett Fishbin | $299 | $244.12 | +37.0% | Oct 31, 2025 |
| Morgan Stanley | David Bailey | $305 | $252.26 | +39.7% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $304 | $271.41 | +39.3% | Oct 21, 2025 |
| Wells Fargo | Analyst unavailable | $280 | $272 | +28.3% | Oct 13, 2025 |
| Morgan Stanley | David Bailey | $286 | $248.14 | +31.0% | May 20, 2025 |
| KeyBanc | Brett Fishbin | $274 | $232.65 | +25.5% | Apr 24, 2025 |
| Mizuho Securities | Anthony Petrone | $265 | $211.49 | +21.4% | Apr 16, 2025 |
| Stifel Nicolaus | Analyst unavailable | $240 | $223.83 | +10.0% | Mar 5, 2025 |
| Piper Sandler | Adam Maeder | $260 | $236.18 | +19.1% | Jan 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $250 | $242.51 | +14.5% | Dec 12, 2024 |
| RBC Capital | Craig Wong-Pan | $224 | $238.95 | +2.6% | Oct 1, 2024 |
| Robert W. Baird | Joe Vruwink | $280 | $246.18 | +28.3% | Sep 23, 2024 |
| Wolfe Research | Mike Polark | $180 | $250.88 | -17.5% | Sep 18, 2024 |
| RBC Capital | Craig Wong-Pan | $187 | $194.27 | -14.3% | Apr 10, 2024 |
| Stifel Nicolaus | Mike Matson | $224 | $198.03 | +2.6% | Apr 1, 2024 |
| Oppenheimer | Suraj Kalia | $175 | $134.65 | -19.8% | Oct 27, 2023 |
| Needham | Mike Matson | $180 | $153.89 | -17.5% | Sep 6, 2023 |
| RBC Capital | Craig Wong-Pan | $244 | $197.57 | +11.8% | Jun 20, 2022 |
| RBC Capital | Analyst unavailable | $233 | $200.81 | +6.7% | Apr 29, 2022 |
| Oppenheimer | Suraj Kalia | $312 | $253.77 | +42.9% | Oct 14, 2021 |
| Morgan Stanley | Sean Laaman | $250 | $271.87 | +14.5% | Aug 4, 2021 |
| Jefferies | Anthony Petrone | $240 | $264.75 | +10.0% | Jul 28, 2021 |
Track every rating change on RMD the moment it posts. Free to start.
Start free